

CITATION REPORT

List of articles citing

A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction

DOI: 10.1016/s0149-2918(03)80328-4
Clinical Therapeutics, 2003, 25, 2709-23.

Source: <https://exaly.com/paper-pdf/35517170/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
89	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246		
88	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. <i>Journal of Pharmacy Practice</i> , 2004 , 17, 239-250	1.3	1
87	[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. <i>Der Urologe</i> , 2004 , 43, 820-8		9
86	Understanding erectile dysfunction medication preference studies. <i>Current Opinion in Urology</i> , 2004 , 14, 367-73	2.8	30
85	Phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>BJU International</i> , 2005 , 96, 257-80	5.6	153
84	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. <i>BJU International</i> , 2005 , 96, 1323-32	5.6	78
83	Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. <i>Clinical Cornerstone</i> , 2005 , 7, 57-65		31
82	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 848-55	1.1	30
81	Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. <i>BMC Urology</i> , 2005 , 5, 18	2.2	43
80	Tadalafil: a clinical update. <i>Aging Health</i> , 2005 , 1, 203-214		3
79	A candid conversation about men, sexual health, and diabetes. <i>The Diabetes Educator</i> , 2005 , 31, 810-7	2.5	9
78	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 75-84	4	43
77	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , 2005 , 65, 1621-50	12.1	133
76	Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. <i>Drugs</i> , 2005 , 65, 2245-51	12.1	24
75	Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. <i>Drugs and Aging</i> , 2005 , 22, 823-44	4.7	17
74	[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. <i>Actas Urológicas Españolas</i> , 2006 , 30, 67-79	0.7	7
73	An overview of the diagnosis and treatment of erectile dysfunction. <i>Drugs</i> , 2006 , 66, 2339-55	12.1	17

72 Oral Therapy for Erectile Dysfunction. **2006**, 271-286

71 Sildenafil in dialysis patients. *International Journal of Artificial Organs*, **2006**, 29, 264-8 1.9 12

70 . **2006**,

69 Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. *BJU International*, **2006**, 98, 623-9 5.6 22

68 Preference studies are of value to the field of sexual medicine: Pro. *Current Sexual Health Reports*, **2006**, 3, 6-8 1.2

67 Preference studies are of value to the field of sexual medicine: Con. *Current Sexual Health Reports*, **2006**, 3, 9-12 1.2

66 Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. *Journal of Sexual Medicine*, **2006**, 3, 901-909 1.1 45

65 Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. *Journal of Sexual Medicine*, **2006**, 3, 1037-1049 1.1 44

64 Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. *European Urology*, **2006**, 49, 30-7 10.2 43

63 Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. *European Urology*, **2006**, 49, 900-7; discussion 907 10.2 16

62 Spinal cord injury: a comprehensive review. *Physical Medicine and Rehabilitation Clinics of North America*, **2007**, 18, 651-79, v 2.3 30

61 Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. *International Journal of Impotence Research*, **2007**, 19, 281-95 2.3 33

60 Comparison of the Efficacy, Safety and Patient Preference of the Phosphodiesterase Type 5 Inhibitors for the Patients with Erectile Dysfunction. *Korean Journal of Urology*, **2007**, 48, 219 5

59 Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). *European Urology*, **2007**, 51, 541-50; discussion 550 10.2 44

58 NHG-Standaard Erectiele disfunctie. *Huisarts En Wetenschap*, **2008**, 51, 381-394 0.1 9

57 Large-scale questionnaire survey of erectile dysfunction drugs in Japanese men. *Reproductive Medicine and Biology*, **2008**, 7, 105-114 4.1 1

56 Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. *Journal of Sexual Medicine*, **2008**, 5, 1198-1207 1.1 47

55 The impact of formulary replacement of sildenafil by vardenafil at a local VA hospital. *International Journal of Impotence Research*, **2008**, 20, 188-91 2.3 2

54	Tadalafil in the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 1315-30	2.9	57
53	Tadalafil versus sildenafil citrate in the treatment of ED: Italian patients' preferences and explanatory notes. <i>Urologia</i> , 2008 , 75, 24-31	1.2	1
52	Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. <i>Patient Preference and Adherence</i> , 2009 , 3, 105-11	2.4	9
51	Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2836-50	1.1	5
50	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , 2009 , 48, 1318, 1320-9		7
49	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. <i>Asian Journal of Andrology</i> , 2009 , 11, 629-37	2.8	1
48	Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. <i>BJU International</i> , 2009 , 103, 1212-7	5.6	39
47	Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. <i>BJU International</i> , 2009 , 103, 1392-5	5.6	32
46	Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 7946-9	8.3	62
45	Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. <i>Drug Safety</i> , 2009 , 32, 1-18	5.1	57
44	Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. <i>Annals of Internal Medicine</i> , 2009 , 151, 639-49	8	58
43	Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2009 , 151, 650-61	8	137
42	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3486-95	3.3	16
41	Treatment of erectile dysfunction in the older diabetic patient. <i>Aging Health</i> , 2010 , 6, 9-29		
40	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2010 , 6, 273-80	4.4	21
39	Treatment of Erectile Dysfunction. 341-354		
38	Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. <i>International Journal of Impotence Research</i> , 2011 , 23, 1-8	2.3	17
37	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <i>Clinical Therapeutics</i> , 2011 , 33, 1590-608	3.5	10

36	Medikament-induzierte Kopfschmerzen. <i>Aktuelle Neurologie</i> , 2012 , 39, 351-357		2
35	Estudio de la eficacia y preferencia de los pacientes con disfunci3n er3ctil grave despu3s de tomar los 3 inhibidores de la fosfodiesterasa 5. <i>Revista Internacional De Androlog3a</i> , 2012 , 10, 139-146	0.6	2
34	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	4	15
33	ADMET considerations for phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1231-45	5.5	12
32	How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2012 , 9, 26-33	1.1	24
31	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , 2013 , 67, 768-80	2.9	73
30	The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. <i>Journal of Sexual Medicine</i> , 2013 , 10, 532-40	1.1	17
29	Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. <i>European Urology</i> , 2013 , 63, 902-12	10.2	157
28	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1333-44	4	72
27	Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1592-602	1.1	26
26	Black tea extract and its thearubigins relieve the sildenafil-induced delayed gut motility in mice: a possible role of nitric oxide. <i>Phytotherapy Research</i> , 2014 , 28, 1687-91	6.7	9
25	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. <i>Human Andrology</i> , 2014 , 4, 45-53	1	
24	Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire. <i>International Journal of Urology</i> , 2014 , 21, 821-5	2.3	8
23	Preference for erectile dysfunction treatments: Assessment by means of consumers' preference analysis techniques. <i>Actas Urol3gicas Espa3olas (English Edition)</i> , 2014 , 38, 319-326	0.1	
22	Preference for erectile dysfunction treatments: Assessment by means of consumers preference analysis techniques. <i>Actas Urol3gicas Espa3olas</i> , 2014 , 38, 319-26	0.7	
21	Sexual Function in Men and Women with Diabetes. 2016 , 716-730		
20	The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 237-47	4.1	39
19	Integrating Sexual Partners into Pharmacological Sex Therapy. 2017 , 453-467		1

18	Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2017 , 49, 1731-1740	2.3	43
17	Les traitements oraux de la dysfonction érectile aujourd'hui, pour quel patient?. <i>Sexologies</i> , 2018 , 27, 37-46	0.5	0
16	The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. <i>Andrology</i> , 2019 , 7, 804-817	4.2	10
15	A "real life" investigation on the prescriptive habits among Italian andrologists: The "CONSER" survey from Italian Society of Andrology (SIA) on Sildenafil oral film. <i>Archivio Italiano Di Urologia Andrologia</i> , 2019 , 91,	1.6	4
14	Erectile Dysfunction. 2019 , 21-32		
13	Pharmacology and perspectives in erectile dysfunction in man. <i>Pharmacology & Therapeutics</i> , 2020 , 208, 107493	13.9	17
12	Sexual Function in Men and Woman with Diabetes. 743-759		1
11	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246		1
10	NHG-Standaard Erectiele disfunctie. 2009 , 1291-1313		
9	NHG-Standaard Erectiele disfunctie. 2011 , 1495-1517		
8	References, Bibliography & Further Reading. 2012 , 287-306		
7	Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial. <i>Asian Journal of Andrology</i> , 2018 , 20, 587-592	2.8	2
6	The Phosphodiesterase-5 Inhibitors and Prostate Cancer [What We Rely Know About It?. <i>Serbian Journal of Experimental and Clinical Research</i> , 2019 ,	0.3	
5	Kopfschmerzen. 2006 , 3-21		
4	Sehstörungen. 2006 , 267-287		
3	Sexuelle Funktionsstörungen. 2008 , 995-1006		
2	Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. <i>Patient Preference and Adherence</i> , 2008 , 2, 149-55	2.4	7
1	Erectile dysfunction. <i>Clinical Evidence</i> , 2011 , 2011,		3

